Welcome to our dedicated page for Chain Bridge I SEC filings (Ticker: CBGGF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Chain Bridge I's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Chain Bridge I's regulatory disclosures and financial reporting.
Chain Bridge I (CBGGF) files a definitive proxy statement describing shareholder votes, financing history and operational timelines. The company raised $230,000,000 in its IPO through $10.00 units and completed a private placement of 10,550,000 warrants that generated $10,550,000. As of November 15, 2021, $234,600,000 of net proceeds were deposited in a Trust Account invested in U.S. government securities pending an Initial Business Combination. On the Record Date there were 6,756,683 outstanding Ordinary Shares. Holders exercised redemptions of 18,848,866 Class A Shares for approximately $197,854,025 and 3,144,451 Class A Shares for approximately $34,500,000 in separate votes. The company seeks shareholder approval to extend its termination date to November 15, 2026 and discloses various non-redemption/backstop agreements, conversion mechanics for Class B shares, certain related-party contributions and the April 7, 2025 termination of the Phytanix Agreement which led to termination of associated non-redemption agreements.
